Tevogen Bio Holdings Inc
For the period ended Dec 31, 2023. Filed Apr 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 29, 2024
TVGN$5.84+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $8,835 | $129,186 |
| Due from related party | 344,500 | — |
| Prepaid expenses and other assets | 2,501 | 145,170 |
| Total current assets | 355,836 | 274,356 |
| Cash and marketable securities held in Trust Account | 16,681,497 | 356,864,000 |
| TOTAL ASSETS | $17,037,333 | $357,138,356 |
| LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $1,142,405 | $210,454 |
| Convertible note payable, net of discount | 1,631,725 | — |
| Due to affiliate | 230,000 | 140,000 |
| Total current liabilities | 3,004,130 | 350,454 |
| Derivative warrant liabilities | 29,000 | 7,250 |
| Deferred underwriting fee payable | 14,700,000 | 14,700,000 |
| Total liabilities | 17,733,130 | 15,057,704 |
| COMMITMENTS AND CONTINGENCIES (Note 6) | - | |
| REDEEMABLE ORDINARY SHARES | ||
| Class A ordinary shares subject to possible redemption, $0.0001 par value, 1,502,180 and 34,500,000 shares at redemption value of $11.10 and $10.34 per share as of December 31, 2023 and 2022, respectively | 16,681,497 | 356,864,000 |
| SHAREHOLDERS’ DEFICIT | ||
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding | — | — |
| Class A ordinary shares; $0.0001 par value; 200,000,000 shares authorized; 13,433,333 and 1,450,000 shares issued and outstanding (excluding 1,502,180 and 34,500,000 shares subject to possible redemption) as of December 31, 2023 and December 31, 2022, respectively | 1,343 | 145 |
| Class B ordinary shares; $0.0001 par value; 20,000,000 shares authorized; 0 and 11,983,333 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | 1,198 |
| Accumulated deficit | (17,378,637) | (14,784,691) |
| Total shareholders’ deficit | (17,377,294) | (14,783,348) |
| TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS’ DEFICIT | $17,037,333 | $357,138,356 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.